Plasma liver-enzyme tests are widely used in the clinic to identify patients with liver diseases, to monitor the course and severity of these diseases and the effect of therapies, and to detect drug-induced liver injury. 1, 2 These tests also have substantial epidemiologic significance that extends beyond the liver, given that they have been shown to be prospective risk factors for type 2 diabetes, cardiovascular disease, and all-cause mortality in multiple large studies. [3] [4] [5] [6] Therefore, it is of interest to identify genes or loci affecting these markers in order to establish whether such loci are also associated with these clinical endpoints. Plasma liver-enzyme levels are influenced by environmental and genetic factors. The estimated heritabilities range from 33% for alanine-aminotransferase (ALT) to 61% for gamma-glutamyl transferase (GGT). 7, 8 So far, only a limited number of genes that influence liverenzyme levels have been identified, mostly those responsible for Mendelian liver diseases such as mutations in the HFE gene in hemochromatosis (MIM 235200). 9, 10 A thorough understanding of the genetic determinants of plasma liver enzymes is important for proper interpretation of these tests. Indeed, such information could assist in our understanding of the interindividual differences in the propensity for development of liver dysfunction in the presence of toxins or conditions such as metabolic syndrome. As such, identification of genes associated with liver-enzyme levels could reveal previously unsuspected candidate genes for liver diseases of viral, metabolic, autoimmune, or toxic origin. The goal of the present study was to identify, by using a genome-wide association (GWA) approach, genes influencing plasma levels of ALT and aspartate-aminotransferase (AST), two markers of hepatocyte injury and liver fat accumulation, and of alkaline phosphatase (ALP) and GGT, used primarily as indicators of biliary or cholestatic diseases and heavy alcohol consumption.
In the discovery phase, we carried out independent GWA studies in three population-based cohorts, the CoLaus Study from Lausanne Switzerland 11, 12 (n ¼ 5636), the the participants are described in Table 2 . The mean levels of liver-enzyme tests varied somewhat between populations, presumably because of slight differences in the demographics of the populations under study and methodological differences in the assays (Table S1 available online) . Accordingly, we used study-specific criteria for GWA-genotyping quality control 11,14 and liver-enzyme-level analyses (Appendix A). Additional genotypes were imputed on the basis of the HapMap Phase II data with the software IMPUTE. 16 For these imputed data, we performed association analysis with SNPTEST, using the full posterior probability genotype distribution for each study separately (adding in relevant covariables). Only SNPs with a posterior probability score >0.90, high genotype information content (proper_info >0.5), and minor allele frequency >0.01 were considered for these imputed association analyses. Quantile-quantile plots ( Figure 1 ) revealed the presence of a substantial number of SNPs associated with ALT, GGT, and ALP levels at a genome-wide significance level (p value < 10 À7 ). No SNP with plasma levels of AST was associated with genome-wide significance. It is not clear why AST was uninformative in this case. Highly significantly associated SNPs were located within discrete regions of the genome (Figure 2) presence of inconsistent direction of the effect across studies or because they did not reach genome-wide significance level (p % 10 À8 ). It is also conceivable that absence of replication was due to LD differences between the European white and Indian Asian cohorts. Out of the 32 replicated SNPs, 19 SNPs were considered to be independent (r 2 < 0.4) ( Table 3 ). These SNPs were located within two loci for ALT, two loci for GGT, and four loci for ALP.
The ALT-associated 10q24.2 region ( Figure S1 ) spans three genes. CHUK (IKK-a) is a ubiquitously expressed serine threonine protein kinase that modulates the NFkB-transcription-factor-dependent activation of several genes implicated in insulin resistance. Its intronic SNP rs11591741 has been reported to be associated with expression of its upstream gene CWF19L1 (CWF19-like 1) in human liver (p ¼ 1.47 3 10 À39 ), 17 probably through its transcriptional regulatory effect. CPN1 encodes arginine carboxypeptidase-1, a liver-expressed plasma metalloprotease that protects the body from potent vasoactive and inflammatory peptides containing C-terminal arginine or lysine (such as kinins or anaphylatoxins), which are released into the circulation. 18, 19 Defects in CPN1 are the cause of carboxypeptidase N deficiency (MIM 212070). ERLIN1 encodes a member of the prohibitin family of proteins that define lipid-raft-like domains of the endoplasmic reticulum. 20 The second association peak for ALT on chromosome 22q13.31 ( Figure S2 ) encompasses a 57 kb fragmented linkage disequilibrium (LD) region encompassing SAMM50 and PNPLA3. SAMM50 is a subunit of mitochondrial SAM translocase complex for importation of proteins such as metabolite-exchange anion-selective channel precursors, 21, 22 whose N-terminal domain is essential for the biogenesis of mitochondria. The variation of imputed SNP rs3761472 (p ¼ 2.7 3 10 À9 )
causes N-terminal Asp110Glu substitution in SAMM50, which may lead to mitochondrial dysfunction and impaired cell growth. PNPLA3 (ADPN) is a liver-expressed transmembrane protein with phospholipase activity. 23 It has been shown to be significantly upregulated during adipocyte differentiation, and in response to fasting and feeding, indicating its role in facilitating both energy mobilization and lipid storage in adipose and liver. 24 PNPLA3
mRNA expression was elevated in subcutaneous and visceral adipose tissue of obese subjects. 25 The lead SNP rs2281135 is in complete LD (r 2 ¼ 1) with intronic SNPs rs1010022 and rs2072907, two obesity-associated tagSNPs that showed significant differences in adipose PNPLA3 mRNA expression and adipocyte lipolysis from experimental data. 25 The effect of the lead SNPs at both CPN1 and PNPLA3 loci was not specific for ALT because these SNPs were also associated with plasma levels of AST (Table 4 ), suggesting that these genes are generally predisposed to hepatocyte dysfunction. When examining the association with GGT levels, we identified a series of SNPs within 300 kb on either side of the gene encoding GGT1 on chromosomal region 22q11.23 ( Figure S3 ). As such, these SNPs met the definition of cis-acting SNPs. 27 The typed rs4820599 (p ¼ 4. suggests that the genetic association observed here is due to differential expression of the gene. Another association peak was observed on chromosomal region 12q24.31 ( Figure S4 ) encompassing HNF1A (TCF-1), the hepatic nuclear factor predominantly expressed in the human liver. This transcriptional regulatory protein plays a prominent role in the activation of a large family of hepatocytespecific genes involved in hepatocyte differentiation and liver development. 29, 30 Mutations within this gene are associated with type III form of maturity-onset diabetes of the young (MODY3 [MIM 600496]) 31 and hepatic adenomas, which are frequently accompanied by an elevation consistent with recently reported observations. 33 It is conceivable that variants within this gene, including imputed rs2464196 (Ser487Asn, p ¼ 3.2 3 10 À12 ) located within the C-terminal transactivation domain of HNF1A, may broadly affect the transcriptional effect of this nuclear factor. The strongest association with ALP levels was observed within the ABO locus on chromosome 9q34.13 ( Figure S5 ). Association between ALP levels and the ABO blood group has been reported previously. 34 This association was specific to plasma ALP (Table 4 ) with SNP rs657152 (p ¼ 1.7 3 10 À30 ) accounting for 2% of the total variance of ALP levels in the CoLaus study (Table S4 ). The mechanism underlying this association remains unclear and may be due to genetically determined variations in the proportion of isoenzymes among different blood types because it has been shown that the appearance of intestinal ALP in the plasma, particularly after fatty meals, is associated with ABO blood group and secretor status. 35 In addition, we detected a strong association with the ALPL locus ( Figure S6 ), which encodes nonspecific alkaline phosphatase found in liver, bone, kidney, and other tissues and is responsible for hypophosphatasia. 36 Association of orthologous ALPL gene with serum ALP levels has been reported in mice 37 but not in humans. One cis-acting SNP rs1780324 within ALPL had been shown to markedly affect the gene expression in lymphoblastoid cells. 28 One trans-acting signal was identified within GPLD1 (glycosylphosphatidylinositol specific phospholipase D1) gene ( Figure S7 ). GPLD1 hydrolyzes the inositol phosphate linkage in proteins anchored by phosphatidylinositol glycans (GPI-anchor), thus releasing these proteins from the membrane. Elevated serum levels of GPLD1 and hepatic mRNA expression have been reported in nonalcoholic fatty liver disease (NAFLD). 38 Finally, one additional trans-acting SNP was localized in the JMJD1C (TRIP8)-REEP3 (receptor accessory protein 3) region. JMJD1C encodes thyroid-hormonereceptor interactor 8, a hormone-dependent transcription factor that regulates expression of a variety of specific target genes 39 ( Figure S8 ). The observation that none of the ALP-associated genes were crossassociated with other liver enzymes ( Table 4 ) may indicate that the association signal was generated by variations in bone-or intestinerather than liver-metabolic pathways. 40 The findings reported here were generated on a limited number of genome-wide scans, and it is anticipated that adding more scans with enriched liver phenotypes within the discovery and replication phase will further expand the number of genes and loci associated with plasma liver-enzyme levels in the population.
At this stage, the discovery of five trans-acting loci and one cis-acting locus influencing plasma levels of liver enzymes may point to mechanisms regulating these enzymes and could assist in the interpretation of liver tests in the clinic. Most importantly, these genes represent candidates for susceptibility to liver diseases. Analysis between variants within these genes and NAFLD, alcohol-, viral, autoimmune, or toxin-induced liver injury is warranted.
Appendix A

Material and Methods
Study Populations. The CoLaus study is a population-based sample consisting of 5694 Lausanne residents aged 35 to 75 years. The study design and protocol have been described previously. 11, 12, 42 The London Life Sciences Population (LOLIPOP) study is an ongoing population-based cohort study of~30,000 Indian Asian and European white men and women, aged 35-75 years, recruited from the lists of 58 general practitioners in West London, United Kingdom. 14, 15 The participants included in the present study are a subset of the LOLIPOP cohort study. These subsets were assembled for specific experiments for identification of genetic variants underlying metabolic syndrome and coronary artery disease (CAD). The samples were genotyped on separate platforms ( Table 1) . The InCHIANTI study is a population-based sample that includes 1200 individuals of <65 age and 1155 individuals of age R65 years. Details of the study design and protocol have been described previously. 13 A total of 1200 subjects who had both WGS data and liver-enzyme levels measured were included in this study. Genome-wide Association Statistics. Linear-regression analyses were done on natural log-transformed ALT, ALP, and AST and power-transformed GGT independently in each study. Regression analyses were done with the PLINK software package 43 adjusted by age, gender, and geographical principle components analyzed by EIGENSOFT software, 44 plus smoking and alcohol intake if they were significant covariates for the trait. Imputation. For CoLaus, InCHIANTI, and LOLIPOP discovery set genotypes were imputed separately on the basis of the HapMap Phase II build35 data with the software IMPUTE. 16 For these imputed data, we performed association analysis with SNPTEST, using the full posteriorprobability genotype distribution for each study separately (adding in relevant covariables). Only SNPs with a posterior probability score >0.90, high genotype information content (proper_info >0.5), and MAF >0.01 were considered for the imputed association analyses. SNP imputation for LOLIPOP substudies used the MACH program (v1.0). For European data sets, CEPH haplotypes in HapMap were used as reference haplotypes. Indian Asian data sets were imputed on the basis of a combination (mixed) of HapMap populations, given that this showed greater concordance with real genotypes, compared with use of any one HapMap population. Imputation analyses were based on HapMap build35, dbSNP build 125. Only SNPs with RSQR R0.3 were considered for the meta-analysis. Meta-analysis. For the initial GWA screen, analyses were performed within study, with study-specific criteria for GWA-genotyping QC and analyses (as described above). We meta-analyzed these summary data by using a fixed-effects model and inverse-variance weighted averages of beta-coefficients to obtain a combined estimate of the overall beta-coefficient and its standard error. Among-study heterogeneity was assessed with the c 2 test.
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